



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet 1 of 2

<b>TRADESMAN</b> <b>INSTITUTE FOR FORM 1449A/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		<b>Complete If Known</b>	
Sheet	1	of	2
		Application Number	10/721,923
		Filing Date	11/25/03
		First Named Inventor	Russell, et al
		Art Unit	1617
		Examiner Name	Jennifer M. Kim
		Attorney Docket Number	DOVP-1-1001 (F:2370-010-03)

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	7/20/06
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

### Complete If Known


Application Number	11/721,923
Filing Date	11/25/03
First Named Inventor	Russell, et al
Art Unit	1617
Examiner Name	Jennifer M. Kim

Attorney Docket Number

DOVP-1-1001 (F:2370-010-03)

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓		CHILMAN-BLAIR, K., et al: "Ocimaplon: Treatment of Generalized Anxiety Disorder GABAA Receptor Modulator. DRUGS OF THE FUTURE, Vol. 28, No. 2, (2003), pp. 115-120.	
		SELLERI, S., et al: "Synthesis, Benzodiazepine Receptor Affinity And In Vivo Testing of 3-aryl-4,7-dihydro-6-(N1'-alkylpyrazol-3'-or 5'-yl)pyrazolo[1,5-a]pyrimidin-7-ones" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, Vol. 32, 1997, pp. 942-953	
		SERRERI, S., et al: "New 2,3-Substituted 4,7-Dihydro-6-(1'H-Pyrazol-3'-YL)Pyrazolo[1,5-A]Pyrimidin-7-Ones and Related Compounds: Synthesis and Benzodiazepine Receptor Binding Study" IL Farmaco, Rome, IT, Vol. 50, No. 10, 1995, pp. 679-687	
		VANOVER, et al., "Discriminative Stimulus And Anxiolytic-Like Effects of the Novel Compound CL 273, 547. EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, Vol. 2, No. 3 (1994) pp. 225-233, Abstract.	
✓		International Search Report (PCT/ISA/220) April 19, 2004	

Examiner Signature		Date Considered	7/20/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2. 01